Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.

MLA

O’Mahony, Brian, et al. “Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1.” Journal of Thrombosis and Haemostasis : JTH, vol. 21, no. 12, Dec. 2023, pp. 3450–62. EBSCOhost, https://doi.org/10.1016/j.jtha.2023.08.032.

APA

O’Mahony, B., Dunn, A. L., Leavitt, A. D., Peyvandi, F., Ozelo, M. C., Mahlangu, J., Peerlinck, K., Wang, J.-D., Lowe, G. C., Tan, C. W., Giermasz, A., Tran, H., Khoo, T.-L., Cockrell, E., Pepperell, D., Chambost, H., López Fernández, M. F., Kazmi, R., Majerus, E., … Pipe, S. W. (2023). Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. Journal of Thrombosis and Haemostasis : JTH, 21(12), 3450–3462. https://doi.org/10.1016/j.jtha.2023.08.032

Chicago

O’Mahony, Brian, Amy L Dunn, Andrew D Leavitt, Flora Peyvandi, Margareth C Ozelo, Johnny Mahlangu, Kathelijne Peerlinck, et al. 2023. “Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1.” Journal of Thrombosis and Haemostasis : JTH 21 (12): 3450–62. doi:10.1016/j.jtha.2023.08.032.